| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Robert D Gaffin | |
| Beata M Wolska | |||
| Marco L Alves | |||
| P2860 | cites work | Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a | Q22010899 |
| Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy | Q22254076 | ||
| Dilated cardiomyopathy mutant tropomyosin mice develop cardiac dysfunction with significantly decreased fractional shortening and myofilament calcium sensitivity | Q24308001 | ||
| Actin mutations in dilated cardiomyopathy, a heritable form of heart failure | Q24310520 | ||
| Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere | Q24316399 | ||
| Mutations in the ANKRD1 gene encoding CARP are responsible for human dilated cardiomyopathy | Q24338214 | ||
| Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy | Q24642218 | ||
| Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy | Q24680224 | ||
| Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure | Q28139275 | ||
| Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy | Q28139470 | ||
| Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy | Q28141697 | ||
| Effects of missense mutations Phe110Ile and Glu244Asp in human cardiac troponin T on force generation in skinned cardiac muscle fibers | Q28143312 | ||
| Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+ desensitization | Q28189045 | ||
| Increased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteins | Q28198289 | ||
| Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy | Q28198707 | ||
| The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility | Q73457987 | ||
| Phosphorylation of phospholamban and troponin I in beta-adrenergic-induced acceleration of cardiac relaxation | Q73532258 | ||
| Lack of association of polymorphisms of the angiotensin converting enzyme and angiotensinogen genes with nonfamilial hypertrophic or dilated cardiomyopathy | Q73623103 | ||
| Cardiomyopathic tropomyosin mutations that increase thin filament Ca2+ sensitivity and tropomyosin N-domain flexibility | Q73756846 | ||
| Re-evaluating sarcoplasmic reticulum function in heart failure | Q74268441 | ||
| A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice | Q74626036 | ||
| EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS | Q76683431 | ||
| Troponin and tropomyosin: proteins that switch on and tune in the activity of cardiac myofilaments | Q77291186 | ||
| Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy | Q77373322 | ||
| AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy | Q77580246 | ||
| Mouse model of a familial hypertrophic cardiomyopathy mutation in alpha-tropomyosin manifests cardiac dysfunction | Q77986125 | ||
| Functional changes in troponin T by a splice donor site mutation that causes hypertrophic cardiomyopathy | Q78117020 | ||
| Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban | Q78117391 | ||
| Troponin phosphorylation and regulatory function in human heart muscle: dephosphorylation of Ser23/24 on troponin I could account for the contractile defect in end-stage heart failure | Q79325476 | ||
| Cardiac aldosterone in subjects with hypertrophic cardiomyopathy | Q79822638 | ||
| Rescue of tropomyosin-induced familial hypertrophic cardiomyopathy mice by transgenesis | Q80116998 | ||
| Hypertrophic cardiomyopathy | Q80172333 | ||
| Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation | Q80447572 | ||
| Beta1- and beta2-adrenergic receptor polymorphisms affect susceptibility to idiopathic dilated cardiomyopathy | Q80712056 | ||
| Beta1-adrenergic receptor gene polymorphisms in Mexican patients with idiopathic dilated cardiomyopathy | Q82602051 | ||
| Beta2-adrenergic receptor polymorphisms and sudden cardiac death: a signal to follow | Q83161951 | ||
| In vivo adenoviral transfer of sorcin reverses cardiac contractile abnormalities of diabetic cardiomyopathy | Q44575124 | ||
| A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy | Q44583245 | ||
| Troponin I phosphorylation plays an important role in the relaxant effect of beta-adrenergic stimulation in mouse hearts | Q44777161 | ||
| Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. | Q44792718 | ||
| Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery | Q45888008 | ||
| A novel mutation of the beta myosin heavy chain gene responsible for familial hypertrophic cardiomyopathy. | Q46128365 | ||
| Levosimendan: from basic science to clinical practice | Q46186787 | ||
| Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy | Q46443112 | ||
| Polymorphisms of the beta-1 and beta-2 adrenergic receptors in Polish patients with idiopathic dilated cardiomyopathy. | Q46589111 | ||
| Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy | Q46743675 | ||
| Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy | Q46822465 | ||
| Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments | Q46954266 | ||
| Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy. | Q47313325 | ||
| Gene transfer of parvalbumin improves diastolic dysfunction in senescent myocytes | Q47406744 | ||
| Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy | Q47747917 | ||
| Parvalbumin corrects slowed relaxation in adult cardiac myocytes expressing hypertrophic cardiomyopathy-linked alpha-tropomyosin mutations | Q47834435 | ||
| Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice | Q48015924 | ||
| Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldos | Q48514325 | ||
| Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases | Q48689994 | ||
| Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium | Q48749719 | ||
| Protein kinase D selectively targets cardiac troponin I and regulates myofilament Ca2+ sensitivity in ventricular myocytes. | Q50695684 | ||
| Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. | Q50911475 | ||
| Angiotensinogen gene polymorphism in Japanese patients with hypertrophic cardiomyopathy. | Q50975604 | ||
| Functional consequences of hypertrophic and dilated cardiomyopathy-causing mutations in alpha-tropomyosin. | Q51389950 | ||
| Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs. | Q51623456 | ||
| Direct effects of 3 combinations of enalapril, metoprolol, and spironolactone on cardiac remodeling in dilated cardiomyopathic hamsters. | Q51801348 | ||
| The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. | Q53963934 | ||
| Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. | Q53965064 | ||
| Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). | Q54093342 | ||
| Actions of sympathomimetic amines on the Ca2+ transients and contractions of rabbit myocardium: reciprocal changes in myofibrillar responsiveness to Ca2+ mediated through alpha- and beta-adrenoceptors. | Q54249385 | ||
| Association of angiotensin-converting enzyme activity and polymorphism with echocardiographic measures in familial and nonfamilial hypertrophic cardiomyopathy. | Q54485567 | ||
| Effects of two hypertrophic cardiomyopathy mutations in alpha-tropomyosin, Asp175Asn and Glu180Gly, on Ca2+ regulation of thin filament motility. | Q54561766 | ||
| [Study on association between aldosterone synthase gene polymorphism and the left ventricular structure and function of patients with dilated cardiomyopathy in China]. | Q54691166 | ||
| Association of beta-adrenergic receptor polymorphisms and progression to heart failure in patients with idiopathic dilated cardiomyopathy. | Q54698967 | ||
| Characterization of a Unique Genetic Variant in the β1-adrenoceptor Gene and Evaluation of its Role in Idiopathic Dilated Cardiomyopathy | Q57606024 | ||
| Familial dilated cardiomyopathy | Q59461183 | ||
| Early Exercise Training Normalizes Myofilament Function and Attenuates Left Ventricular Pump Dysfunction in Mice With a Large Myocardial Infarction | Q62476637 | ||
| Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan | Q70791977 | ||
| Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+ | Q71404454 | ||
| CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction | Q71435059 | ||
| Angiotensin-converting enzyme gene polymorphism in Japanese patients with hypertrophic cardiomyopathy | Q71550580 | ||
| Angiotensin-I Converting Enzyme Genotypes and Left Ventricular Hypertrophy in Patients With Hypertrophic Cardiomyopathy | Q72050276 | ||
| Cardiac troponin I phosphorylation increases the rate of cardiac muscle relaxation | Q72256359 | ||
| Beta-adrenergic receptor stimulation increases unloaded shortening velocity of skinned single ventricular myocytes from rats | Q72269926 | ||
| Transgenic modeling of a cardiac troponin I mutation linked to familial hypertrophic cardiomyopathy | Q73134348 | ||
| Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy | Q73288500 | ||
| Altered regulation of cardiac muscle contraction by troponin T mutations that cause familial hypertrophic cardiomyopathy | Q73316865 | ||
| The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation | Q73318669 | ||
| The in vitro motility activity of beta-cardiac myosin depends on the nature of the beta-myosin heavy chain gene mutation in hypertrophic cardiomyopathy | Q73388735 | ||
| Cardiac excitation-contraction coupling | Q28216347 | ||
| Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy | Q28244969 | ||
| Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy | Q28264486 | ||
| Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C | Q28284750 | ||
| Protein kinase D is a novel mediator of cardiac troponin I phosphorylation and regulates myofilament function | Q28290449 | ||
| Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans | Q28302847 | ||
| Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy | Q28344111 | ||
| Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy | Q28348531 | ||
| Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | Q28354203 | ||
| The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 | ||
| Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy | Q28505358 | ||
| Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy | Q28506679 | ||
| Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy | Q28570951 | ||
| Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts | Q28572323 | ||
| Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy | Q28588821 | ||
| Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy | Q28589243 | ||
| Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T | Q28590907 | ||
| Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. | Q28594348 | ||
| Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. | Q30484558 | ||
| R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level | Q30656473 | ||
| Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation | Q31685225 | ||
| Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay | Q33277814 | ||
| Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. | Q33894656 | ||
| Phospholamban and cardiac contractile function | Q33927760 | ||
| Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy | Q33947464 | ||
| Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. | Q34060513 | ||
| Targeting phospholamban by gene transfer in human heart failure | Q34074819 | ||
| The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study | Q34086740 | ||
| Hypertrophic cardiomyopathy: a systematic review | Q34117625 | ||
| Invited Review: pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation | Q34142086 | ||
| Functional analysis of myosin mutations that cause familial hypertrophic cardiomyopathy. | Q34169619 | ||
| Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death | Q34335461 | ||
| Progression of left ventricular hypertrophy and the angiotensin-converting enzyme gene polymorphism in hypertrophic cardiomyopathy | Q34341637 | ||
| Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy | Q39747918 | ||
| Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. | Q40821260 | ||
| Phospholamban-to-SERCA2 ratio controls the force-frequency relationship | Q41611935 | ||
| Clinical and genetic characteristics of alpha cardiac actin gene mutations in hypertrophic cardiomyopathy. | Q43045174 | ||
| Transgenic expression of sarcoplasmic reticulum Ca(2+) atpase modifies the transition from hypertrophy to early heart failure | Q43726347 | ||
| Myofilament properties comprise the rate-limiting step for cardiac relaxation at body temperature in the rat. | Q43852667 | ||
| Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation | Q43978631 | ||
| Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation | Q44008015 | ||
| Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status | Q44092122 | ||
| Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade | Q44095817 | ||
| Combined effects of enalapril and spironolactone in hamsters with dilated cardiomyopathy | Q44261008 | ||
| Functional Importance of the Carboxyl-terminal Region of Striated Muscle Tropomyosin | Q44400069 | ||
| Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy | Q44454565 | ||
| Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy | Q44479128 | ||
| ??? | Q28304085 | ||
| MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure | Q34416947 | ||
| From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease | Q34433378 | ||
| Modifier genes for hypertrophic cardiomyopathy | Q34641881 | ||
| Structural analysis of obscurin gene in hypertrophic cardiomyopathy | Q34666945 | ||
| Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy | Q34714041 | ||
| The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model | Q34790975 | ||
| Calcium cycling in congestive heart failure | Q34863566 | ||
| Phenotypic diversity in hypertrophic cardiomyopathy | Q34915396 | ||
| Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure | Q34978011 | ||
| Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy | Q34992640 | ||
| The role of tropomyosin in the regulation of myocardial contraction and relaxation | Q35104953 | ||
| The pathology of hypertrophic cardiomyopathy | Q35771667 | ||
| Role of troponin T in disease. | Q35938326 | ||
| Clinical and genetic issues in familial dilated cardiomyopathy | Q36088694 | ||
| The genetic basis for cardiac remodeling | Q36241650 | ||
| Sarcomeric protein mutations in dilated cardiomyopathy | Q36369921 | ||
| Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes | Q36369925 | ||
| Genes, calcium and modifying factors in hypertrophic cardiomyopathy | Q36381489 | ||
| p21-Activated kinase-1 and its role in integrated regulation of cardiac contractility | Q36869603 | ||
| Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? | Q36919149 | ||
| The cardioprotective effects of levosimendan: preclinical and clinical evidence | Q36945501 | ||
| A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure | Q37000342 | ||
| The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study | Q37024682 | ||
| The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation | Q37045891 | ||
| Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins | Q37196012 | ||
| Molecular etiology and pathogenesis of hereditary cardiomyopathy | Q37261168 | ||
| Dilated cardiomyopathy: a review. | Q37328772 | ||
| Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure | Q37352397 | ||
| Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome | Q37362212 | ||
| The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure | Q37385715 | ||
| Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation | Q37410985 | ||
| Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy | Q37546327 | ||
| Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry | Q37677635 | ||
| Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy | Q38441528 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 834-842 | |
| P577 | publication date | 2010-01-15 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes | |
| P478 | volume | 48 |
| Q35559000 | Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications |
| Q39613583 | Arginylation regulates myofibrils to maintain heart function and prevent dilated cardiomyopathy. |
| Q33771564 | Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins |
| Q34561038 | Functional effects of a tropomyosin mutation linked to FHC contribute to maladaptation during acidosis |
| Q26852120 | Integration of troponin I phosphorylation with cardiac regulatory networks |
| Q34582867 | Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A. |
| Q28242903 | Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy |
| Q35565337 | Long-term rescue of a familial hypertrophic cardiomyopathy caused by a mutation in the thin filament protein, tropomyosin, via modulation of a calcium cycling protein |
| Q35172648 | Mechanistic heterogeneity in contractile properties of α-tropomyosin (TPM1) mutants associated with inherited cardiomyopathies. |
| Q90638593 | Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response |
| Q26865973 | Myosin binding protein C: implications for signal-transduction |
| Q36339491 | N-acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy |
| Q92240141 | Novel Therapies for Prevention and Early Treatment of Cardiomyopathies |
| Q27694507 | Research priorities in sarcomeric cardiomyopathies |
| Q36823735 | Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy |
| Q39404059 | Therapeutic Strategies Targeting Inherited Cardiomyopathies |
| Q28307606 | Thin filament mutations: developing an integrative approach to a complex disorder |
| Q30245043 | Update on hypertrophic cardiomyopathy and a guide to the guidelines. |
Search more.